Kaplan BL et al. |
Inhibition of leukocyte function and interleukin-2 gene expression by 2-methylarachidonyl-(2'-fluoroethyl)amide, a stable congener of the endogenous cannabinoid receptor ligand anandamide. |
2005 |
Toxicol. Appl. Pharmacol. |
pmid:15893538
|
Quistad GB et al. |
Fatty acid amide hydrolase inhibition by neurotoxic organophosphorus pesticides. |
2001 |
Toxicol. Appl. Pharmacol. |
pmid:11350214
|
Kodani SD et al. |
Parabens inhibit fatty acid amide hydrolase: A potential role in paraben-enhanced 3T3-L1 adipocyte differentiation. |
2016 |
Toxicol. Lett. |
pmid:27659731
|
Carr RL et al. |
Effect of developmental chlorpyrifos exposure, on endocannabinoid metabolizing enzymes, in the brain of juvenile rats. |
2011 |
Toxicol. Sci. |
pmid:21507991
|
Carr RL et al. |
Induction of endocannabinoid levels in juvenile rat brain following developmental chlorpyrifos exposure. |
2013 |
Toxicol. Sci. |
pmid:23761300
|
Hsu SS et al. |
Anandamide-induced Ca2+ elevation leading to p38 MAPK phosphorylation and subsequent cell death via apoptosis in human osteosarcoma cells. |
2007 |
Toxicology |
pmid:17222495
|
Bluett RJ et al. |
Central anandamide deficiency predicts stress-induced anxiety: behavioral reversal through endocannabinoid augmentation. |
2014 |
Transl Psychiatry |
pmid:25004388
|
Leweke FM et al. |
Cannabidiol enhances anandamide signaling and alleviates psychotic symptoms of schizophrenia. |
2012 |
Transl Psychiatry |
pmid:22832859
|
Maccarrone M et al. |
Intracellular trafficking of anandamide: new concepts for signaling. |
2010 |
Trends Biochem. Sci. |
pmid:20570522
|
Alhouayek M and Muccioli GG |
The endocannabinoid system in inflammatory bowel diseases: from pathophysiology to therapeutic opportunity. |
2012 |
Trends Mol Med |
pmid:22917662
|
Gaetani S et al. |
Anandamide hydrolysis: a new target for anti-anxiety drugs? |
2003 |
Trends Mol Med |
pmid:14604824
|
Maccarrone M |
Inhibition of anandamide hydrolysis: cells also know how to do it. |
2004 |
Trends Mol Med |
pmid:14720580
|
Mechoulam R et al. |
Cannabinoids and brain injury: therapeutic implications. |
2002 |
Trends Mol Med |
pmid:11815270
|
Szallasi A and Di Marzo V |
New perspectives on enigmatic vanilloid receptors. |
2000 |
Trends Neurosci. |
pmid:11006466
|
Devane WA |
New dawn of cannabinoid pharmacology. |
1994 |
Trends Pharmacol. Sci. |
pmid:8165721
|
Zygmunt PM et al. |
Anandamide - the other side of the coin. |
2000 |
Trends Pharmacol. Sci. |
pmid:10664604
|
Smart D and Jerman JC |
Anandamide: an endogenous activator of the vanilloid receptor. |
2000 |
Trends Pharmacol. Sci. |
pmid:10740287
|
Fowler CJ |
Has FLAT fallen flat? |
2014 |
Trends Pharmacol. Sci. |
pmid:24398120
|
Randall MD and Kendall DA |
Endocannabinoids: a new class of vasoactive substances. |
1998 |
Trends Pharmacol. Sci. |
pmid:9550942
|
Di Marzo V et al. |
Anandamide: some like it hot. |
2001 |
Trends Pharmacol. Sci. |
pmid:11431028
|